Research programme: oral tryptase inhibitors - Molecumetics/Choongwae Pharma

Drug Profile

Research programme: oral tryptase inhibitors - Molecumetics/Choongwae Pharma

Alternative Names: Tryptase inhibitors research programme - Molecumetics/Choongwae Pharma

Latest Information Update: 19 Sep 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecumetics
  • Class
  • Mechanism of Action Tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Asthma; Inflammatory bowel diseases; Psoriasis

Most Recent Events

  • 08 Sep 1999 New profile
  • 08 Sep 1999 This programme is available for licensing in Europe, North America and Japan (
  • 08 Sep 1999 Preclinical development for Asthma in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top